CDKN1A and prostate carcinoma: Therefore, data reported from many studies about anticancer role of fisetin against different prostate cancer cell lines (CWR22Rupsilon1, LNCaP, and PC‐3) investigated that treatment of fisetin with different doses (10–60 microM, 48 hr) significantly found to lower the viability and exhibit cell cycle arrest at G(1) phase, momentous reduction in levels of protein (cyclins D1, D2, and E), and their activating partner cyclin‐dependent kinases 2, 4, and 6 with concomitant induction of WAF1/p21 and KIP1/p27.